Bladder Cancer Market Analysis by Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others), By Treatment (Surgery, Chemotherapy, Immunotherapy Radiation Therapy, Others), By Major Tests (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Bladder Ultrasound), By End-Users (Hospitals, Specialty Clinics, Others) and by Region: Global Forecast, 2024 - 2034
- PUBLISHED ON
- 2024-04-17
- NO OF PAGES
- 191
- CATEGORY
- Healthcare & Life Sciences
Market Overview
The Bladder Cancer market is predicted to develop at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2034, when it is projected to reach USD 536.25 Million, based on an average growth pattern. The market is estimated to reach a value of USD 339.13 Million in 2024.
SOURCE: We Market Research
The cells that
line the bladder's interior are the source of bladder cancer. It is primarily
transitional cell carcinoma, though it can also appear as adenocarcinoma or
squamous cell carcinoma. Risk factors include age, gender, family history,
chemical exposure, chronic bladder problems, and smoking. Blood in the urine,
frequent urination, and pelvic pain are typical signs. Depending on the stage
of the cancer, different treatments may be used, such as immunotherapy,
radiation therapy, chemotherapy, or surgery. A better prognosis depends on
early identification, which is typically achieved by routine tests for
high-risk patients. Getting medical help as soon as symptoms appear improves
bladder cancer treatment efficacy and overall results.
The bladder
cancer market is expanding globally due to a number of causes are, growing
incidence rates are driving up need for cutting-edge diagnostics and therapies,
particularly among the elderly population. Personalized therapy and early
diagnosis are being made possible by technological breakthroughs, especially in
the areas of molecular diagnostics and imaging. Market expansion is further
aided by rising healthcare spending, rising awareness, and screening programs.
Furthermore, potential treatment alternatives are being offered by continuing
research and development initiatives, particularly in the areas of
immunotherapy and targeted treatments. When combined, these forces are
reshaping the bladder cancer treatment landscape, fostering innovation, and
enhancing patient outcomes.
Market Scope
|
Report Attributes |
Description |
|
Market Size in 2024 |
USD 339.13 Million |
|
Market Forecast in 2034 |
USD 536.25Million |
|
CAGR % 2024-2034 |
5.7% |
|
Base Year |
2023 |
|
Historic Data |
2016-2022 |
|
Forecast Period |
2024-2034 |
|
Report USP
|
Production, Consumption, company share, company
heatmap, company production capacity, growth factors and more |
|
Segments Covered |
By Type, By Treatment, By Major Tests, By End-Users and By Region |
|
Regional Scope |
North America, Europe, APAC, South America and
Middle East and Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic
Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia;
Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa;
Nigeria |
Bladder Cancer Industry: Dynamics & Restrains
We Market Research: Bladder Cancer Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Bladder Cancer Segmentation
Market- By Type Analysis
By Type, the Bladder Cancer Market is Categories into Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others. The Transitional Cell Bladder Cancer segment accounts for the largest share of around 72% in 2024.
Transitional Cell Bladder Cancer is
primarily driven by smoking, occupational exposure to chemicals, chronic
bladder irritation, genetic factors, age/gender, and exposure to aristolochic
acid, leading to DNA damage and cancer development.
The
following segments are part of an in-depth analysis of the global Bladder
Cancer market:
|
Market Segments |
|
|
By Treatment |
·
Surgery ·
Chemotherapy ·
Immunotherapy Radiation
Therapy ·
Others |
|
By Major
Tests |
·
Cystoscopy ·
Biopsy ·
Urinalysis ·
Urine Cytology ·
Bladder Ultrasound |
|
By End-Users |
·
Hospitals ·
Specialty Clinics ·
Others |
Bladder Cancer Industry: Regional Analysis
North America Market Forecast
North America dominate the Bladder Cancer Market with the highest revenue generating market with share of more than 47%. High incidence linked to aging populations, a culture of extensive smoking, and well-established healthcare systems that allow for early detection and cutting-edge treatment options, which improve survival chances.
Asia Pacific Market Statistics
Asia Pacific region is the second largest
market in Bladder Cancer, due to the Rising incidence driven on by increased
smoking rates, exposure to environmental carcinogens (such as industrial
pollution), and more information has increased the need for supportive care and
effective bladder cancer therapies throughout the region.
Europe Market Forecasts
Europe is
expected to be the fastest-growing regional segment of the Bladder Cancer
market during the forecast period. In the Europe region, common smoking habits,
an aging population at risk for cancer, exposure to industrial pollutants,
well-established healthcare systems that enable early detection, sedentary
lifestyles and diets, and possible genetic predispositions that contribute to
the development of the disease are the main causes of bladder cancer in Europe.
Key Market Players
·
Pfizer Inc.
·
Johnson & Johnson
·
Astellas Pharma Inc.
·
Eli Lilly and Company
·
GlaxoSmithKline plc
·
Bayer AG
·
Seattle Genetics Inc.
·
Sanofi S.A.
·
Novartis AG
·
Merck & Co. Inc.
·
Hoffmann-La Roche Ltd.
· AstraZeneca PLC
· Other
1.
Global
Bladder Cancer Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global Bladder Cancer Market
Scope and Market Estimation
1.2.1. Global Bladder Cancer Overall
Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)
1.2.2. Global Bladder Cancer Market
Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034
1.3. Market Segmentation
1.3.1. Component of Global Bladder
Cancer Market
1.3.2. Technology of Global Bladder
Cancer Market
1.3.3. Major Tests of Global Bladder
Cancer Market
1.3.4. Region of Global Bladder Cancer
Market
2.
Executive Summary
2.1. Global Bladder Cancer Market Industry Trends under COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global Bladder Cancer Market
Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and
Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global Bladder Cancer Market Estimates & Historical Trend Analysis (2019 -
2023)
4.
Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by
TYPE
4.1. Global Bladder Cancer Market
Revenue (US$ Mn) Estimates and Forecasts, by TYPE, 2019 to 2034
4.1.1. Transitional Cell Bladder Cancer
4.1.2. Superficial Bladder Cancer
4.1.3. Invasive Bladder Cancer
4.1.4. Squamous Cell Bladder Cancer
4.1.5. Others
5.
Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by
Treatment
5.1. Global Bladder Cancer Market
Revenue (US$ Mn) Estimates and Forecasts, by Treatment, 2019 to 2034
5.1.1. Surgery
5.1.2. Chemotherapy
5.1.3. Immunotherapy Radiation Therapy
5.1.4. Others
6.
Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by
Major Tests
6.1. Global Bladder Cancer Market
Revenue (US$ Mn) Estimates and Forecasts, by Major Tests,
2019 to 2034
6.1.1. Cystoscopy
6.1.2. Biopsy
6.1.3. Urinalysis
6.1.4. Urine Cytology
6.1.5. Bladder Ultrasound
7.
Global Bladder Cancer Market Estimates & Forecast Trend Analysis, by
END-USERS
7.1. Global Bladder Cancer Market
Revenue (US$ Mn) Estimates and Forecasts, by Major Tests,
2019 to 2034
7.1.1. Hospitals
7.1.2. Specialty Clinics
7.1.3. Others
8.
Global Bladder Cancer Market Estimates & Forecast Trend Analysis,
by Region
8.1. Global Bladder Cancer Market
Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9.
North
America Bladder Cancer Market: Estimates & Forecast Trend Analysis
9.1.
North
America Bladder Cancer Market Assessments & Key Findings
9.1.1. North America Bladder Cancer
Market Introduction
9.1.2. North America Bladder Cancer
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
9.1.2.1. By TYPE
9.1.2.2. By Treatment
9.1.2.3. By Major Tests
9.1.2.4. By END-USERS
9.1.2.5. By Country
9.1.2.5.1. The U.S.
9.1.2.5.2. Canada
9.1.2.5.3. Mexico
10. Europe Bladder
Cancer Market: Estimates & Forecast
Trend Analysis
10.1. Europe Bladder Cancer Market
Assessments & Key Findings
10.1.1. Europe Bladder Cancer Market
Introduction
10.1.2. Europe Bladder Cancer Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
10.1.2.1. By TYPE
10.1.2.2. By Treatment
10.1.2.3. By Major Tests
10.1.2.4. By END-USERS
10.1.2.5. By Country
10.1.2.5.1. Germany
10.1.2.5.2. U.K.
10.1.2.5.3. France
10.1.2.5.4. Italy
10.1.2.5.5. Spain
10.1.2.5.6. Russia
10.1.2.5.7. Rest of Europe
11. Asia Pacific Bladder
Cancer Market: Estimates & Forecast
Trend Analysis
11.1. Asia Pacific Market Assessments
& Key Findings
11.1.1. Asia Pacific Bladder Cancer
Market Introduction
11.1.2. Asia Pacific Bladder Cancer
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
11.1.2.1. By TYPE
11.1.2.2. By Treatment
11.1.2.3. By Major Tests
11.1.2.4. By END-USERS
11.1.2.5. By Country
11.1.2.5.1. China
11.1.2.5.2. Japan
11.1.2.5.3. India
11.1.2.5.4. Australia
11.1.2.5.5. South Korea
11.1.2.5.6. ASEAN
11.1.2.5.7. Rest of Asia Pacific
12. Middle East & Africa Bladder
Cancer Market: Estimates & Forecast
Trend Analysis
12.1. Middle East & Africa Market
Assessments & Key Findings
12.1.1. Middle
East & Africa Bladder
Cancer Market Introduction
12.1.2. Middle
East & Africa Bladder
Cancer Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
12.1.2.1. By TYPE
12.1.2.2. By Treatment
12.1.2.3. By Major Tests
12.1.2.4. By END-USERS
12.1.2.5. By Country
12.1.2.5.1. U.A.E.
12.1.2.5.2. Saudi Arabia
12.1.2.5.3. Egypt
12.1.2.5.4. South Africa
12.1.2.5.5. Rest of Middle East & Africa
13. South America
Bladder Cancer Market: Estimates &
Forecast Trend Analysis
13.1. South America Market Assessments
& Key Findings
13.1.1. South America Bladder Cancer
Market Introduction
13.1.2. South America Bladder Cancer
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
13.1.2.1. By TYPE
13.1.2.2. By Treatment
13.1.2.3. By Major Tests
13.1.2.4. By END-USERS
13.1.2.5. By Country
13.1.2.5.1. Brazil
13.1.2.5.2. Argentina
13.1.2.5.3. Colombia
13.1.2.5.4. Rest of South America
14. Competition Landscape
14.1. Global Bladder Cancer Market
Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
14.2. Global Bladder Cancer Market
Competition White Space Analysis, By Major Tests
14.3. Global Bladder Cancer Market
Competition Heat Map Analysis, By Major Tests
14.4. Global Bladder Cancer Market
Concentration & Company Market Shares (%) Analysis, 2022
15. Company Profiles
15.1.
Pfizer Inc.
15.1.1. Company Overview & Key Stats
15.1.2. Financial Performance & KPIs
15.1.3. Product Portfolio
15.1.4. Business Strategy & Recent Developments
* Similar details would be provided
for all the players mentioned below
15.2. Johnson &
Johnson
15.3. Astellas
Pharma Inc.
15.4. Eli Lilly and
Company
15.5. GlaxoSmithKline
plc
15.6. Bayer AG
15.7. Seattle
Genetics Inc.
15.8. Sanofi S.A.
15.9. Novartis AG
15.10. Merck &
Co. Inc.
15.11. Hoffmann-La
Roche Ltd.
15.12. AstraZeneca
PLC
15.13. Others
16. Research
Methodology
16.1. External Transportations /
Databases
16.2. Internal Proprietary Database
16.3. Primary Research
16.4. Secondary Research
16.5. Assumptions
16.6. Limitations
16.7. Report FAQs
17. Research
Findings & Conclusion
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Frequently Asked Questions
What is the market size of Bladder Cancer Market in 2024?
Bladder Cancer Market was valued at USD 339.13 Million in 2024.
What is the growth rate for the Bladder Cancer Market?
Bladder Cancer Market size will increase at approximate CAGR of 5.7% during the forecasted period.
Which are the top companies operating within the market?
Major companies operating within the Bladder Cancer Market Are Pfizer Inc., Johnson & Johnson, Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Bayer AG, Seattle Genetics Inc., Sanofi S.A., Novartis AG, Merck & Co. Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC and Others.
Which region dominates the Bladder Cancer Market?
North America dominates the market with an active share of 47%.
}})
Select a license type that suits your business needs
US $3499
Only Three Thousand Four Hundred Ninety Nine US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4499
Only Four Thousand Four Hundred Ninety Nine US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5499
Only Five Thousand Four Hundred Ninety Nine US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI